NewsBenzingaヴィリディアン・セラピューティクス、VRDN-008の第1相試験結果を発表;皮下投与後8週間にわたり深く持続的なIgG低下を示し、ピーク時に74%低下を達成 ヴィリディアン・セラピューティクス、VRDN-008の第1相試験結果を発表;皮下投与後8週間にわたり深く持続的なIgG低下を示し、ピーク時に74%低下を達成 Benzinga 2026.11.09 12:12 (GMT+0) Open on Benzinga Other news Is Wall Street Bullish or Bearish on Zimmer Biomet Stock? Clorox Stock Outlook: Is Wall Street Bullish or Bearish? Shorting ConocoPhillips Puts and Put Credit Spreads Are Attractive Income Plays Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report How To Earn $500 A Month From Target Stock Ahead Of Q3 Earnings Stifel Reinstates Buy on Walmart, Announces $145 Price Target
Trump Administration Shrugs Off Big Tech Warnings, Advances Plan to Restrict Chinese Data Center Gear Despite Compliance Woes: Report